PMID- 28598267
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1557-8976 (Electronic)
IS  - 0882-8245 (Print)
IS  - 0882-8245 (Linking)
VI  - 30
IP  - 7
DP  - 2017 Sep
TI  - Interaction of Immunoglobulin with Cytomegalovirus-Infected Cells.
PG  - 500-507
LID - 10.1089/vim.2016.0151 [doi]
AB  - Intravenous immunoglobulin (IVIG) is used to treat or prevent severe viral 
      infection, especially cytomegalovirus (CMV) infections. IVIG was characterized to 
      understand its interaction with CMV-infected cells. IVIG retarded CMV spread and 
      reduced virus yields depending on the neutralizing (NT) antibody titer. Immediate 
      early protein synthesis was reduced by IVIG in 3 to 15 h, and IVIG specifically 
      reduced the ratio of 66/68k protein synthesis among immediate early proteins in 
      an NT antibody-dependent manner between 4 and 8 h after infection, indicating 
      that antigenic modulation of CMV-infected cells by IVIG reduced viral protein 
      synthesis and virus production. The half-life of antibody bound to CMV-infected 
      cells was 3.8 h. NT antibody titers to varicella-zoster virus (VZV) and CMV in 
      IVIG were dose dependently absorbed by cells infected with VZV and CMV, 
      respectively, but the antibody titers to CMV and VZV, respectively, were not 
      affected. NT antibody in 0.3 mL of IVIG (15 mg) was specifically absorbed by 
      10(8) CMV-infected cells and 10(7) VZV-infected cells, suggesting that the NT 
      antibody in IVIG might be inactivated by one-tenth of a similar volume of 
      CMV-infected or VZV-infected cells. Various antiviral activities of IVIG may 
      contribute to control and alleviation of CMV infection.
FAU - Aiba, Nobuyasu
AU  - Aiba N
AD  - 1 Health Care Center, Takaoka Fushiki Hospital , Takaoka City, Japan .
FAU - Shiraki, Atsuko
AU  - Shiraki A
AD  - 2 Department of Virology, University of Toyama , Toyama City, Japan .
FAU - Yajima, Misako
AU  - Yajima M
AD  - 2 Department of Virology, University of Toyama , Toyama City, Japan .
FAU - Oyama, Yukari
AU  - Oyama Y
AD  - 2 Department of Virology, University of Toyama , Toyama City, Japan .
FAU - Yoshida, Yoshihiro
AU  - Yoshida Y
AD  - 2 Department of Virology, University of Toyama , Toyama City, Japan .
FAU - Ohno, Ayumu
AU  - Ohno A
AD  - 2 Department of Virology, University of Toyama , Toyama City, Japan .
FAU - Yamada, Hiroshi
AU  - Yamada H
AD  - 2 Department of Virology, University of Toyama , Toyama City, Japan .
FAU - Takemoto, Masaya
AU  - Takemoto M
AD  - 3 Faculty of Pharmaceutical Sciences, Hokuriku University , Kanazawa City, Japan 
      .
FAU - Daikoku, Tohru
AU  - Daikoku T
AD  - 3 Faculty of Pharmaceutical Sciences, Hokuriku University , Kanazawa City, Japan 
      .
FAU - Shiraki, Kimiyasu
AU  - Shiraki K
AD  - 2 Department of Virology, University of Toyama , Toyama City, Japan .
LA  - eng
PT  - Journal Article
DEP - 20170609
PL  - United States
TA  - Viral Immunol
JT  - Viral immunology
JID - 8801552
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Antiviral Agents)
RN  - 0 (Immediate-Early Proteins)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Antibodies, Neutralizing/*immunology
MH  - Antibodies, Viral/immunology
MH  - Antigenic Modulation
MH  - Antiviral Agents/immunology
MH  - Cells, Cultured
MH  - Cytomegalovirus/*immunology
MH  - Cytomegalovirus Infections/*immunology
MH  - Humans
MH  - Immediate-Early Proteins/metabolism
MH  - Immunoglobulin G/*immunology/metabolism
MH  - Immunoglobulins, Intravenous/immunology
MH  - Neutralization Tests
MH  - Virus Release/immunology
PMC - PMC5610397
OTO - NOTNLM
OT  - ADCC
OT  - antigenic modulation
OT  - cytomegalovirus
OT  - intravenous immunoglobulin
OT  - varicella-zoster virus
COIS- No competing financial interests exist.
EDAT- 2017/06/10 06:00
MHDA- 2018/12/12 06:00
PMCR- 2018/09/01
CRDT- 2017/06/10 06:00
PHST- 2017/06/10 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2017/06/10 06:00 [entrez]
PHST- 2018/09/01 00:00 [pmc-release]
AID - 10.1089/vim.2016.0151 [pii]
AID - 10.1089/vim.2016.0151 [doi]
PST - ppublish
SO  - Viral Immunol. 2017 Sep;30(7):500-507. doi: 10.1089/vim.2016.0151. Epub 2017 Jun 
      9.